Longduoduo Company Limited (LDDD)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Longduoduo Company Limited (LDDD) with AI Score 51/100 (Hold). Longduoduo Company Limited provides preventive healthcare solutions in China, focusing on cardiovascular and cerebrovascular diseases. Sector: Healthcare.
Last analyzed: Mar 15, 2026LDDD: the 1 perspectives are evenly split.
Longduoduo Company Limited (LDDD) Healthcare & Pipeline Overview
Longduoduo Company Limited delivers preventive healthcare solutions in China, addressing cardiovascular and cerebrovascular diseases. Their services encompass disease screening, treatments, and healthcare products distributed via third-party channels. Operating in the diagnostics and research segment, the company caters to a growing demand for preventive care in the Chinese market.
What Is the Investment Thesis for LDDD?
Longduoduo Company Limited presents a speculative investment opportunity within the Chinese preventive healthcare market. The company's focus on cardiovascular and cerebrovascular disease prevention aligns with growing health concerns and government support for proactive healthcare measures. However, the company's negative P/E ratio of -51.82 and negative profit margin of -10.9% indicate financial challenges. The high gross margin of 98.5% suggests potential for profitability if operational efficiencies improve. Key growth catalysts include expanding service offerings and penetrating new geographic regions within China. Investors should carefully consider the risks associated with investing in a small-cap OTC-listed company with limited financial history.
Based on FMP financials and quantitative analysis
LDDD Key Highlights
- Market capitalization of $0.02 billion indicates a small-cap company with potential for high growth but also higher risk.
- Negative P/E ratio of -51.82 reflects current unprofitability, requiring careful monitoring of future earnings.
- High gross margin of 98.5% suggests strong pricing power or a focus on high-value services.
- Beta of 1.53 indicates higher volatility compared to the overall market.
- No dividend yield reflects a focus on reinvesting earnings for growth.
Who Are LDDD's Competitors?
What Are LDDD's Key Strengths?
- Specialized focus on cardiovascular and cerebrovascular disease prevention.
- Comprehensive range of preventive healthcare services and products.
- Established network of third-party healthcare providers and sales agents.
- Innovative treatment offerings such as meridian-regulating iatrotechnics.
What Are LDDD's Weaknesses?
- Limited operating history as the company was founded in 2020.
- Negative P/E ratio and profit margin indicate financial challenges.
- Small market capitalization and OTC listing increase investment risk.
- Dependence on third-party providers and sales agents.
What Could Drive LDDD Stock Higher?
- Potential partnerships with hospitals and clinics to expand service reach.
- Expansion of service offerings to include new preventive healthcare treatments.
- Development and launch of new healthcare products.
- Leveraging telemedicine and digital health platforms to improve patient engagement.
What Are the Key Risks for LDDD?
- Intense competition from established healthcare providers in China.
- Changes in government regulations and healthcare policies could impact the company's operations.
- Economic slowdown in China could reduce demand for preventive healthcare services.
- Limited financial disclosure increases investment risk.
- Low trading volume and liquidity can lead to price volatility.
What Are the Growth Opportunities for LDDD?
- Expansion into New Geographic Regions: Longduoduo can expand its services to other regions within China, targeting areas with high prevalence of cardiovascular and cerebrovascular diseases. The Chinese healthcare market is vast, offering significant growth potential for companies that can effectively penetrate new regions. This expansion could involve establishing new partnerships with local healthcare providers and sales agents. Timeline: Ongoing.
- Development of New Preventive Healthcare Products: Longduoduo can invest in research and development to create new preventive healthcare products that complement its existing service offerings. These products could include dietary supplements, medical devices, or digital health solutions. The market for preventive healthcare products is growing rapidly, driven by increasing consumer awareness and demand for proactive health management. Timeline: Ongoing.
- Strategic Partnerships with Hospitals and Clinics: Forming strategic partnerships with hospitals and clinics can provide Longduoduo with access to a wider patient base and enhance its credibility. These partnerships can involve offering Longduoduo's services within the hospital or clinic setting, or co-developing new preventive healthcare programs. The hospital and clinic market in China is large and fragmented, offering numerous partnership opportunities. Timeline: Ongoing.
- Leveraging Telemedicine and Digital Health Platforms: Longduoduo can leverage telemedicine and digital health platforms to expand its reach and improve patient engagement. This can involve offering online consultations, remote monitoring, and personalized health coaching. The digital health market in China is growing rapidly, driven by increasing internet penetration and the adoption of mobile health technologies. Timeline: Ongoing.
- Focus on Personalized Healthcare Solutions: Tailoring preventive healthcare solutions to individual patient needs can improve outcomes and enhance patient satisfaction. This can involve using genetic testing, lifestyle assessments, and other data to develop personalized treatment plans. The market for personalized healthcare is growing, driven by advances in genomics and data analytics. Timeline: Ongoing.
What Opportunities Does LDDD Have?
- Expansion into new geographic regions within China.
- Development of new preventive healthcare products and services.
- Strategic partnerships with hospitals and clinics.
- Leveraging telemedicine and digital health platforms.
What Threats Does LDDD Face?
- Intense competition from established healthcare providers.
- Changes in government regulations and healthcare policies.
- Economic slowdown in China.
- Potential for product liability claims.
What Are LDDD's Competitive Advantages?
- Specialized treatment offerings like meridian-regulating iatrotechnics and double blood purification.
- Focus on the specific market of cardiovascular and cerebrovascular disease prevention in China.
- Established network of third-party healthcare service providers and sales agents.
- Proprietary healthcare products and treatment protocols.
What Does LDDD Do?
Founded in 2020 and headquartered in Hohhot, China, Longduoduo Company Limited operates within the preventive healthcare sector, focusing on solutions for cardiovascular and cerebrovascular diseases. The company's inception was driven by the increasing prevalence of these conditions in China and the growing demand for proactive healthcare measures. Longduoduo offers a suite of preventive healthcare services, including disease screening, healthcare treatments, and healthcare products. These services are designed to mitigate the risks associated with myocardial infarction, cerebral infarction, hemiplegia, and other related conditions. The company utilizes a network of third-party healthcare service providers, product suppliers, and sales agents to deliver its offerings to the market. Longduoduo's service portfolio includes specialized treatments such as meridian-regulating and consciousness restoring iatrotechnics, double blood purification, immunological ozonated autohemotherapy, platelet-rich plasma, relaxation therapy, vegetative nerve regulation, and microwave therapy. These diverse therapeutic approaches aim to provide comprehensive preventive care to its clientele. While a relatively young company, Longduoduo is strategically positioned to capitalize on the expanding healthcare market in China, driven by increasing health awareness and government initiatives promoting preventive care.
What Products and Services Does LDDD Offer?
- Provides disease screening services for early detection of health risks.
- Offers healthcare treatments focused on preventing cardiovascular and cerebrovascular diseases.
- Distributes healthcare products designed to promote overall wellness and disease prevention.
- Delivers meridian-regulating and consciousness restoring iatrotechnics.
- Offers double blood purification services.
- Provides immunological ozonated autohemotherapy.
- Administers platelet-rich plasma therapy.
- Offers relaxation therapy, vegetative nerve regulation, and microwave therapy.
How Does LDDD Make Money?
- Generates revenue through the provision of preventive healthcare services.
- Sells healthcare products through third-party distributors and sales agents.
- Partners with healthcare providers to offer services within their facilities.
- Focuses on preventing myocardial infarction, cerebral infarction, hemiplegia, and cardiovascular and cerebrovascular diseases.
What Industry Does LDDD Operate In?
Longduoduo Company Limited operates in the growing Chinese healthcare market, specifically within the preventive healthcare segment. The demand for preventive care is increasing due to rising healthcare awareness and government initiatives promoting early disease detection and management. The market is competitive, with established players and emerging companies offering various preventive healthcare solutions. Longduoduo differentiates itself through its specialized treatments and focus on cardiovascular and cerebrovascular diseases. The company's success depends on its ability to effectively market its services, establish strong partnerships, and maintain high-quality standards.
Who Are LDDD's Key Customers?
- Individuals seeking preventive healthcare solutions in China.
- Patients at risk of cardiovascular and cerebrovascular diseases.
- Healthcare providers who partner with Longduoduo to offer preventive services.
- Consumers interested in purchasing healthcare products for disease prevention.
LDDD Financials
LDDD Latest News
No recent news available for LDDD.
LDDD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LDDD.
Price Targets
Wall Street price target analysis for LDDD.
LDDD MoonshotScore
What does this score mean?
The MoonshotScore rates LDDD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Who Are LDDD's Competitors?
Leadership: Hongxiao Zhou
CEO
Hongxiao Zhou is the CEO of Longduoduo Company Limited, leading a team of 52 employees. His background includes experience in the healthcare sector, with a focus on preventive care and disease management. Prior to joining Longduoduo, Zhou held various leadership positions in healthcare companies, where he was responsible for developing and implementing strategic initiatives. He has a strong understanding of the Chinese healthcare market and the challenges and opportunities it presents. Zhou is committed to driving Longduoduo's growth and success by providing innovative and effective preventive healthcare solutions.
Track Record: Since founding Longduoduo in 2020, Hongxiao Zhou has focused on establishing the company's presence in the Chinese preventive healthcare market. Key milestones under his leadership include developing a comprehensive range of preventive healthcare services and products, establishing a network of third-party healthcare providers and sales agents, and securing partnerships with key stakeholders in the healthcare industry. Zhou's strategic decisions have positioned Longduoduo for future growth and success.
LDDD OTC Market Information
The OTC Other tier, also known as the Pink tier, represents the most speculative and least regulated segment of the OTC market. Companies in this tier often have limited financial disclosure, may be distressed, or may not meet the minimum requirements for higher OTC tiers like OTCQB or OTCQX. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to stocks listed on major exchanges like the NYSE or NASDAQ. These companies may not be current in their reporting requirements.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in LDDD.
- Low trading volume and liquidity can lead to price volatility.
- OTC Other tier listing indicates a higher level of risk compared to stocks listed on major exchanges.
- Potential for fraud or manipulation due to the lack of regulatory oversight.
- Uncertainty regarding the company's long-term viability and financial stability.
- Verify the company's registration and legal standing.
- Attempt to obtain and review any available financial statements.
- Assess the company's management team and their track record.
- Research the company's industry and competitive landscape.
- Understand the company's business model and revenue streams.
- Evaluate the risks associated with investing in an OTC-listed company.
- Consult with a financial advisor before making any investment decisions.
- Company has been in operation since 2020.
- Focus on preventive healthcare solutions aligns with growing market demand.
- Presence of a CEO and management team.
- Company has 52 employees.
Common Questions About LDDD (Healthcare)
What does Longduoduo Company Limited do?
Longduoduo Company Limited is a preventive healthcare solutions provider based in China, focusing on cardiovascular and cerebrovascular diseases. The company offers a range of services, including disease screening, healthcare treatments, and healthcare products, delivered through third-party healthcare service providers, product suppliers, and sales agents. Their specialized treatments include meridian-regulating iatrotechnics, double blood purification, and immunological ozonated autohemotherapy, targeting the prevention of serious conditions like myocardial infarction and cerebral infarction.
What do analysts say about LDDD stock?
As of March 15, 2026, there is no available analyst coverage for Longduoduo Company Limited (LDDD) due to its small market capitalization and OTC listing. Key valuation metrics such as P/E ratio (-51.82) and profit margin (-10.9%) indicate current unprofitability. Investors should conduct their own thorough research and consider the risks associated with investing in a small-cap OTC-listed company before making any investment decisions. The high gross margin of 98.5% is a positive indicator, but needs to be balanced against the other financial metrics.
What are the main risks for LDDD?
The main risks for Longduoduo Company Limited include intense competition from established healthcare providers in China, potential changes in government regulations and healthcare policies, and the risk of an economic slowdown in China affecting demand for preventive healthcare services. Additionally, the company's limited financial disclosure and OTC listing increase investment risk due to lower regulatory oversight and potential for price volatility. Investors should carefully consider these risks before investing in LDDD.
What are the key factors to evaluate for LDDD?
Longduoduo Company Limited (LDDD) currently holds an AI score of 51/100, indicating moderate score. Key strength: Specialized focus on cardiovascular and cerebrovascular disease prevention. Primary risk to monitor: Intense competition from established healthcare providers in China. This is not financial advice.
How frequently does LDDD data refresh on this page?
LDDD prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven LDDD's recent stock price performance?
Recent price movement in Longduoduo Company Limited (LDDD) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized focus on cardiovascular and cerebrovascular disease prevention. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider LDDD overvalued or undervalued right now?
Determining whether Longduoduo Company Limited (LDDD) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying LDDD?
Before investing in Longduoduo Company Limited (LDDD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be limited due to the company's OTC listing and disclosure status.
- AI analysis pending for LDDD.